Jazz Pharmaceuticals
JAZZ
231.19
-0.20
-0.09%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
231.19
-0.20
-0.09%
Live - 5344 symbols - heartbeat 35s ago
· 2026-10-08 04:15
Pre-market
229.85
-0.58%
After-hours
231.19
0.00%
Overnight
231.85
+0.29%
- Market cap
- 15.01B
- P/E (TTM)i
- 15.82
- P/Bi
- 3.13
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on JAZZ?
Anonymous reader poll. Unscientific, not investment advice.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
- Founded
- 2005
- CEO
- Ms. Renee D. Gala
- Employees
- 2,890
- Headquarters
- Dublin, Dublin, Ireland
- Fiscal year end
- 12-31
- Website
- jazzpharma.com
Company profile
- Exchange
- US
- Symbol
- JAZZ
- Market-cap rank
- #1123
- Listing date
- 1970-01-01
- Market cap
- 15.01B
- Float cap
- 14.56B
- Shares out
- 64.91M
- Float shares
- 62.98M
Sectors & themes
Quote time 2026-10-08 04:15:57 · For reference only, not investment advice and not tailored to your situation.